Clinical trials: Carcinoma of Lung
Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor
Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have…
- Trial name
- BOOST (NCT07073365)
- Testing
- Local Therapy (Surgery or Radiotherapy)
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Pusan National University Hospital
NSCLC (Non-small-cell Lung Cancer)
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer (NSCLC)
- Trial name
- NCT05118334
- Testing
- Sintilimab, IBI310
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy.
- Trial name
- NCT00048087
- Testing
- ZD1839, Docetaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer Stage III
Accelerated Radio-Immunotherapy for Lung Cancer
Radiotherapy (RT), at a total dose of 60-66 Gy over 6 weeks, combined with platinum-based chemotherapy, is the standard of care for stage III Non-Small Cell Lung Cancers (NSCLC) patients with unresectable or inoperable disease.
- Trial name
- AIRING (NCT04577638)
- Testing
- Nivolumab and Intensity Modulated Radiotherapy (IMRT)
- Where
- 5 sites in France
- Volunteers
- 8 people
- Sponsor
- Center Eugene Marquis
Hemoptysis, Haemoptysis
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.
- Conditions
- Hemoptysis, Haemoptysis, Lung Disease, Pneumonia
- Trial name
- NCT02913365
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Université de Sherbrooke
Non-Small Cell Lung Cancer, Myelosuppression
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment.
- Trial name
- PROTECT-1 (NCT06929936)
- Testing
- Trilaciclib combined with Docetaxel
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumors
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy…
- Trial name
- NCT05599984
- Testing
- ABBV-706, Cisplatin, Budigalimab
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 288 people
- Sponsor
- AbbVie
Melanoma, Non Small Cell Lung Cancer
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- CHECK'UP (NCT03412058)
- Testing
- Biopsy
- Where
- 19 sites in France
- Volunteers
- 152 people
- Sponsor
- UNICANCER
Small Cell Lung Cancer Extensive Stage
Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.
The goal of this clinical trial is to learn the efficacy and safety of tislelizumab in combination with chemotherapy(etoposide/cisplatin ) ± concurrent radiotherapy for extensive-stage oligometastatic small cell lung cancer.
- Trial name
- TERE (NCT06851819)
- Testing
- radiotherapy, immunechemotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Hebei Medical University Fourth Hospital
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Non-Small Cell Lung Cancer Stage, Chemoradiation
Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer
The aim of this study is to evaluate the feasibility and the effect of daily, individual, supervised and structured exercise training before radiotherapy in patients diagnosed with Non-Small Cell Lung Cancer.
- Trial name
- PRIME (NCT03066271)
- Testing
- Exercise +, Control +
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell…
- Conditions
- Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
- Trial name
- PD-L1-PET (NCT06690216)
- Testing
- PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Man Hu
Lung Cancer
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as MK-0646, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00869752
- Testing
- anti-IGF-1R recombinant monoclonal antibody MK-0646, cisplatin, etoposide
- Where
- 3 sites in Canada
- Volunteers
- 12 people
- Sponsor
- NCIC Clinical Trials Group
Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired.
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT07104630
- Testing
- Pulmonary Rehabilitation (PR), No intervention: Usual care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus…
- Trial name
- NCT00243867
- Testing
- Taxoprexin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- American Regent, Inc.
NSCLC Stage IV
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT04633564
- Testing
- Bevacizumab as MYL-1402O, Bevacizumab as Avastin
- Where
- 102 sites in Belarus, Bosnia and Herzegovina and 15 more
- Volunteers
- 671 people
- Sponsor
- Mylan Pharmaceuticals Inc
Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03948763
- Testing
- V941, Pembrolizumab
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Complication of Surgical Procedure
Comparison of LigaSure to Conventional Electrocoagulation in Video-assisted Thoracoscopic Surgery Lobectomy
Surgical treatment of lung cancer consists of two elements: anatomical lung resection (segmentectomy, lobectomy or pneumonectomy) followed by mediastinal lymph node dissection (MLND).
- Trial name
- NCT03125798
- Testing
- LigaSure™, Monopolar electrocautery
- Where
- Poland
- Volunteers
- 216 people
- Sponsor
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine